RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 81 filers reported holding RECRO PHARMA INC in Q2 2018. The put-call ratio across all filers is 2.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $13,000 | -97.3% | 4,700 | -98.0% | 0.00% | -100.0% |
| Q3 2020 | $489,000 | +11.1% | 233,100 | +140.8% | 0.00% | 0.0% |
| Q2 2020 | $440,000 | +633.3% | 96,800 | +1208.1% | 0.00% | – |
| Q1 2020 | $60,000 | -55.6% | 7,400 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $135,000 | -25.0% | 7,400 | -54.9% | 0.00% | – |
| Q3 2019 | $180,000 | -69.2% | 16,400 | -71.5% | 0.00% | -100.0% |
| Q2 2019 | $584,000 | +63.6% | 57,500 | -5.7% | 0.00% | +50.0% |
| Q1 2019 | $357,000 | -34.1% | 61,000 | -20.2% | 0.00% | -33.3% |
| Q4 2018 | $542,000 | -16.5% | 76,400 | -16.3% | 0.00% | 0.0% |
| Q3 2018 | $649,000 | -3.3% | 91,300 | -31.8% | 0.00% | 0.0% |
| Q2 2018 | $671,000 | -4.1% | 133,800 | +110.4% | 0.00% | 0.0% |
| Q1 2018 | $700,000 | +241.5% | 63,600 | +186.5% | 0.00% | +200.0% |
| Q4 2017 | $205,000 | +485.7% | 22,200 | +455.0% | 0.00% | – |
| Q3 2017 | $35,000 | +25.0% | 4,000 | 0.0% | 0.00% | – |
| Q2 2017 | $28,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 2,202,420 | $6,145,000 | 3.11% |
| Samjo Capital LLC | 560,000 | $1,562,000 | 1.16% |
| MAK CAPITAL ONE LLC | 1,224,264 | $3,416,000 | 0.81% |
| Cowen Prime Services LLC | 470,500 | $1,313,000 | 0.50% |
| Portolan Capital Management | 1,957,283 | $5,461,000 | 0.43% |
| Parkman Healthcare Partners LLC | 601,967 | $1,679,000 | 0.39% |
| Rubric Capital Management LP | 1,076,587 | $3,004,000 | 0.18% |
| Frontier Wealth Management LLC | 49,112 | $2,142,000 | 0.16% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 466,992 | $1,303,000 | 0.16% |
| AWM Investment Company, Inc. | 391,304 | $1,092,000 | 0.12% |